Coherus BioSciences Inc. (CHRS)

21.74
NASDAQ : Health Technology
Prev Close 20.57
Day Low/High 20.28 / 21.92
52 Wk Low/High 8.32 / 23.43
Avg Volume 1.03M
Exchange NASDAQ
Shares Outstanding 69.76M
Market Cap 1.44B
EPS -3.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
Coherus BioSciences Enters Oversold Territory (CHRS)

Coherus BioSciences Enters Oversold Territory (CHRS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Coherus BioSciences (CHRS) Highlighted As Weak On High Volume

Coherus BioSciences (CHRS) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Coherus BioSciences (CHRS) as a weak on high relative volume candidate

Coherus BioSciences Reports Update To CHS-1701 Program

Coherus BioSciences Reports Update To CHS-1701 Program

Pegfilgrastim Follow-on PK/PD Study Added to Bolster BLA Submission Package

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAL, AIRM, BDX, KMX, LPTH, MCOX, WGP Downgrades: CHEV, CIGI, DBD, HBHC, MRVL, NNI, ONP, REXR, RRD, TGS, TOO, WES, WIFI Initiations: CHRS, FGBI, FRPT, INCR, NVRO, TBK, UPLD, XENE Read on to get TheStreet Quant Ratings' detailed report:

Coherus BioSciences Reports Third Quarter 2015 Financial And Operating Results And Corporate Events

Coherus BioSciences Reports Third Quarter 2015 Financial And Operating Results And Corporate Events

Pegfilgrastim PK/PD Study Completed and Adalimumab Phase 3 Study Initiated

Coherus Announces Topline Results Of CHS-1701 Pharmacokinetic And Pharmacodynamic Biosimilarity Study

Coherus Announces Topline Results Of CHS-1701 Pharmacokinetic And Pharmacodynamic Biosimilarity Study

BLA Submission Targeted for the First Quarter of 2016

Oversold Conditions For Coherus BioSciences

Oversold Conditions For Coherus BioSciences

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Put Impax, Akorn and Sagent on Your Watch List of Generics Targets

Put Impax, Akorn and Sagent on Your Watch List of Generics Targets

If companies such as Teva and Perrigo continue to seek growth through acquisitions, they may gobble up Impax Laboratories, Akorn Pharmaceuticals or Sagent Pharmaceuticals.

Coherus BioSciences Reports Second Quarter 2015 Financial And Operating Results

Coherus BioSciences Reports Second Quarter 2015 Financial And Operating Results

Pegfilgrastim BLA-Enabling Studies Progressing and Etanercept Phase 3 Studies Enrolled

Short Interest In Coherus BioSciences Jumps 41.2%

Short Interest In Coherus BioSciences Jumps 41.2%

The most recent short interest data has been released by the NASDAQ for the 07/15/2015 settlement date, which shows a 790,316 share increase in total short interest for Coherus BioSciences Inc , to 2,707,236, an increase of 41.23% since 06/30/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Coherus BioSciences Reports First Quarter 2015 Financial And Operating Results

Coherus BioSciences Reports First Quarter 2015 Financial And Operating Results

Pegfilgrastim Progressing to BLA-Enabling Studies

This Isn't What This Market Needs

A flood of supply in a nervous market isn't a good idea.

TheStreet Quant Rating: D- (Sell)